FDA Seeks Comments on Prescription Drug Import Data Collection
Published Date: 4/16/2026
Notice
Summary
The FDA wants your thoughts on how they collect info about importing prescription drugs. This affects drug companies and anyone involved in bringing meds into the U.S. You’ve got until June 15, 2026, to share your comments—no cost to join, just your voice! The goal? Make sure the rules are clear and easy to follow.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Recordkeeping Burden for Importation Sponsors
If you are a Section 804 Importation Program (SIP) Sponsor, an importer (pharmacist or wholesale distributor), or a drug manufacturer, FDA estimates the paperwork burden at 100 total annual records and 6,040 hours per year. Specifically, Subpart B is estimated at 60 records at 72 hours each (4,320 hours) and Subpart C at 40 records at 43 hours each (1,720 hours).
Section 804 Aims to Lower Drug Costs
The purpose of section 804 of the Federal Food, Drug, and Cosmetic Act is to reduce the cost of covered prescription products to American consumers without imposing additional risks to public health and safety. The regulations in 21 CFR part 251 set procedures for SIP Sponsors to submit plans for time-limited programs to begin importation of drugs from Canada and establish criteria for FDA review and authorization.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-07420, Publishing.com, LLC, Christian Mikkelsen, and Rasmus Mikkelsen; Analysis of Proposed Consent Order To Aid Public Comment
Publishing.com, LLC and the Mikkelsen brothers are facing charges for unfair or deceptive business practices. They’ve agreed to stop these actions under a proposed deal, and the public has until May 18, 2026, to share their thoughts. This means changes for the company and no money penalties are mentioned yet, but everyone’s watching closely!
Next: 2026-07422, Determination of Regulatory Review Period for Purposes of Patent Extension; UNLOXCYT
The FDA has set the official review period for UNLOXCYT, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind UNLOXCYT and anyone interested in patent timing or drug development. If you think the dates are wrong or want to challenge the company’s diligence, you have until mid-2026 to speak up—potentially impacting patent length and market exclusivity.